22 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy https://www.zacks.com/stock/news/2199442/vertex-vrtx-crispr-get-positive-chmp-opinion-for-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199442 Dec 18, 2023 - Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324 Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198026 Dec 14, 2023 - bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197830 Dec 14, 2023 - Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
1 Biotech Stock That Could Be the Next Amgen https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/?source=iedfolrf0000001 Dec 13, 2023 - The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies https://www.zacks.com/stock/news/2196355/blue-crsp-vrtx-down-despite-fda-nod-to-scd-therapies?cid=CS-ZC-FT-analyst_blog|industry_focus-2196355 Dec 11, 2023 - The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD https://www.zacks.com/stock/news/2196255/bluebird-blue-down-despite-fda-nod-to-gene-therapy-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196255 Dec 11, 2023 - bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy https://www.zacks.com/stock/news/2196180/crispr-crsp-vertex-fall-despite-fda-nod-to-scd-drug-casgevy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196180 Dec 11, 2023 - CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.
Is This News a Setback or a Step Forward for CRISPR Therapeutics? https://www.fool.com/investing/2023/12/06/is-this-setback-or-step-forward-for-crispr/?source=iedfolrf0000001 Dec 06, 2023 - It's important to look at the news through a long-term lens.
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794 Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

Pages: 123

<Page 2